U.S. markets open in 1 hour 3 minutes

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8600-0.0500 (-1.28%)
At close: 4:00PM EDT
3.8600 0.00 (0.00%)
Pre-Market: 08:19AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close3.9100
Open3.9100
Bid0.0000 x 1300
Ask4.1500 x 800
Day's Range3.7600 - 3.9600
52 Week Range1.9300 - 11.5800
Volume614,622
Avg. Volume1,068,490
Market Cap425.746M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-1.2610
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
    GlobeNewswire

    Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer

    CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Regulatory Officer, Dr. Iman Barilero. The grant was approved by a majority of the independent directors of the Company on May 5, 2021 as an inducement material to Dr. Barilero entering into employment with the Company in

  • Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
    GlobeNewswire

    Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer

    CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective June 1, 2021. Dr. Barilero brings three decades of experience as a strategic executive in the healthcare industry, successfully designing innovative and integrated regulatory pathways that gained re

  • Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference
    GlobeNewswire

    Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference

    CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 3:30 p.m. ET. A live webcast of this presentation will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event. About Solid BiosciencesSolid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.Investor Contact:David CareyFINN Partners212-867-1768David.Carey@finnpartners.com Media Contact:Erich SandovalFINN Partners917-497-2867Erich.Sandoval@finnpartners.com